Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard D Press

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Blood|August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trialsSusan Branford, Linda Fletcher, Nicholas C P Cross, et al.
Cancer Cell|August 30, 2024
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapyChristopher A Eide, Diana Brewer, Tao Xie, et al.
American Journal of Hematology|August 30, 2007
Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screeningJames C Barton, Ronald T Acton, Catherine Leiendecker-Foster, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 7, 2021
Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutationsLaura F Newell, Jennifer Dunlap, Ken Gatter, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracyLeyuan Ma, Jeffrey I Boucher, Janet Paulsen, et al.
Transplantation and Cellular Therapy|April 26, 2021
Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or RelapseLaura F Newell, Todd Williams, James Liu, et al.
Academic Pathology|August 18, 2017
The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient CareKaren L Kaul, Linda M Sabatini, Gregory J Tsongalis, et al.
Haematologica|February 13, 2025
Oncogenic <i>NTRK3</i> mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemiaSunil K Joshi, Ariane Huang, Janét Pittsenbarger, et al.
American Journal of Hematology|November 18, 2015
Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanismMichael R Garbati, Catherine A Welgan, Sally H Landefeld, et al.
Blood|August 24, 2011
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasmsAngela G Fleischman, Karl J Aichberger, Samuel B Luty, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Blood|August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trialsSusan Branford, Linda Fletcher, Nicholas C P Cross, et al.
Cancer Cell|August 30, 2024
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapyChristopher A Eide, Diana Brewer, Tao Xie, et al.
American Journal of Hematology|August 30, 2007
Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screeningJames C Barton, Ronald T Acton, Catherine Leiendecker-Foster, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 7, 2021
Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutationsLaura F Newell, Jennifer Dunlap, Ken Gatter, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracyLeyuan Ma, Jeffrey I Boucher, Janet Paulsen, et al.
Transplantation and Cellular Therapy|April 26, 2021
Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or RelapseLaura F Newell, Todd Williams, James Liu, et al.
Academic Pathology|August 18, 2017
The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient CareKaren L Kaul, Linda M Sabatini, Gregory J Tsongalis, et al.
Haematologica|February 13, 2025
Oncogenic <i>NTRK3</i> mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemiaSunil K Joshi, Ariane Huang, Janét Pittsenbarger, et al.
American Journal of Hematology|November 18, 2015
Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanismMichael R Garbati, Catherine A Welgan, Sally H Landefeld, et al.
Blood|August 24, 2011
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasmsAngela G Fleischman, Karl J Aichberger, Samuel B Luty, et al.
Pageof 6